Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

749.04 +2.68 (+0.36%)
Streaming Delayed Price Updated: 11:16 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
News headline image
1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
News headline image
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential. 
Via MarketBeat
Topics Government World Trade
News headline image
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
News headline image
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
News headline image
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. 
Via MarketBeat
Topics ETFs Economy Government
News headline image
REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%... 
Via StockStory
News headline image
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
News headline image
3 of Wall Street’s Favorite Stocks Skating on Thin Ice
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 to Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Thursday. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Thursday's session: gap up and gap down stock in the S&P500 index ↗
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
News headline image
Price Over Earnings Overview: Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
News headline image
4 Dividend Stocks to Buy on the Pullback ↗
Take advantage of cheap prices 
Via The Motley Fool
News headline image
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Despite its impressive fundamentals,REGENERON PHARMACEUTICALS (NASDAQ:REGN) remains undervalued. ↗
REGENERON PHARMACEUTICALS has caught the attention as a great value stock. NASDAQ:REGN excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
News headline image
Top S&P500 movers in Wednesday's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
Regeneron Shares Are Up Today: What's Going On? ↗
Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.